Cold paresis in multifocal motor neuropathy

Abstract

Increased weakness during cold (cold paresis) was reported in single cases of multifocal motor neuropathy (MMN). This was unexpected because demyelination is a feature of MMN and symptoms of demyelination improve, rather than worsen, in cold. It was hypothesized that cold paresis in MMN does not reflect demyelination only, but may indicate the existence of inflammatory nerve lesions with permanently depolarized axons that only just conduct at normal temperature, but fail at lower temperatures. We investigated symptoms of cold paresis in 50 MMN patients, 48 chronic inflammatory demyelinating polyneuropathy (CIDP) patients, 35 progressive spinal muscular atrophy (PSMA) patients, and 25 chronic idiopathic axonal polyneuropathy patients. We also investigated symptoms of increased weakness during warmth (heat paresis). Cold paresis was reported more often than heat paresis. Cold paresis was most frequently reported in MMN. Multivariate analysis indicated that MMN patients had a 4- to 6-fold higher risk of reporting cold paresis than CIDP or PSMA patients. Because cold paresis is not consistent with demyelination, the lesions in MMN may involve other mechanisms than demyelination only. In conclusion, symptoms of cold paresis are common in peripheral nervous system disorders, particularly in MMN. This supports the above-described hypothesis.

Introduction

The effect of temperature on symptoms of neurological disorders is complicated and has not been fully explored, neither in patients, nor in physiological research. A well-known effect is the worsening of symptoms in multiple sclerosis after a hot bath [20, 25]. In peripheral neuropathies, similar effects were described. In a patient with chronic inflammatory demyelinating polyneuropathy (CIDP), symptoms considerably increased during fever and in seven patients with various demyelinating neuropathies, electrophysiological signs of conduction block increased after warming and decreased after cooling [4, 8, 20]. This so-called heat paresis may occur in demyelinating disorders and is caused by an unfavorable combination of factors that block saltatory conduction between an active node of Ranvier and the node that is next to be activated. First, paranodal demyelination results in current leakage at the node-to-be-activated, so that less current is available to depolarize this node [11]. Secondly, raising temperature will decrease sodium-channel open time at the active node [6, 21]. This yields a further decrease in the current available to depolarize the node-to-be-activated. If there is just sufficient current available to sustain action potential propagation at a demyelinated internode, an additional decrease in current due to rising temperature may, therefore, induce conduction block as was shown in single demyelinated internodes [19].

In the authors’ experience, however, patients with peripheral nervous system disorders often state that weakness during cold increases. This cold paresis is not consistent with the above-described mechanism because that would lead to less weakness in cold. Whether or not cold paresis is really common and if it is related to specific disorders has not been investigated. Furthermore, the mechanisms of cold paresis are not clear. Cold paresis was only reported in single cases of multifocal motor neuropathy (MMN) and in patients with Hirayama disease [11, 23]. To explain cold paresis in MMN, Kaji hypothesized the existence of inflammatory nerve lesions with permanently depolarized axons that only just conduct at normal temperature [11]. At lower temperatures, Na/K-pump activity decreases due to the thermal reduction of its ATP-ase activity; this may cause additional depolarization, yielding depolarizing conduction block and weakness [9–11]. Recent findings from our group supported the hypothesis of Kaji by showing that cooling indeed induced depolarization of human motor axons, and that this depolarization was best explained by decreased pump-activity [7]. Since, in the future, such axons may possibly be saved from degeneration by neuroprotective treatment, cold paresis may become an important symptom [13, 22, 30].

The present study was not conducted to investigate the mechanism of cold paresis but to assess if symptoms of cold paresis are common in MMN and if they are specific for MMN. If cold paresis were a common symptom, it may instigate further research into its mechanisms. If cold paresis were specific for MMN, it may form a clue for the pathogenesis of MMN, which is currently unknown. We investigated the frequency of symptoms of cold paresis and heat paresis in a large group of patients with MMN. Control groups included CIDP, sporadic progressive spinal muscular atrophy (PSMA), and chronic idiopathic axonal polyneuropathy (CIAP).

Materials and methods

Patients

A cross-sectional study was performed by sending a questionnaire to 60 patients with MMN, 60 with CIDP, 50 with sporadic PSMA, and 35 patients with CIAP. All patients had weakness in arm or leg muscles on neurological examination. The questionnaire was returned by 83% of MMN, 80% of CIDP, 70% of PSMA, and 71% of CIAP patients. For each group, the patients who did not return the questionnaire did not differ significantly from the patients who returned the questionnaire with respect to sex, age, and disease duration (data not shown). Patient characteristics are presented in Table 1. Two patients in the PSMA group had Hirayama disease. The patients attended the outpatient clinics of the University Medical Center in Utrecht, a tertiary referral center for neuromuscular disorders in the Netherlands. Diagnoses were based on criteria sets for MMN [28], CIDP [1], sporadic PSMA [29], and CIAP [16]. In these sets, the criteria for conduction block were adapted [27, 28]. All MMN patients were on intravenous immunoglobulins (IVIg) maintenance treatment. Twenty-eight patients with CIDP were treated with IVIg, with 20 patients responding favorably. Twelve patients with CIDP were treated with steroids, with 11 patients responding favorably. Of the remaining CIDP patients, two were successfully treated with cyclophosphamide and six were not treated. None of the patients had concomitant diseases of the central or peripheral nervous system. All participants gave informed consent to participate in the study, which was approved by the Medical Ethical Committee of the University Medical Center Utrecht.

Table 1.

Baseline characteristics

Patient group	Male (%)	Age (years)	Disease duration (years)	Weakness arm (%)	Weakness leg (%)	CB arm nerves (%)	CB leg nerves (%)
MMN (n = 50)	82	51 (33–74)	10 (2–39)	100	68	68	24
CIDP (n = 48)	58	54 (22–82)	4 (0–32)	88	96	44	19
PSMA (n = 35)	86	61 (35–83)	12 (4–30)	86	51	0	0
CIAP (n = 25)	80	75 (61–89)	13 (4–21)	28	100	0	0

Age and disease duration are given as median (range)

CB conduction block; MMN multifocal motor neuropathy; CIDP chronic inflammatory demyelinating polyneuropathy; PSMA progressive spinal muscular atrophy; CIAP chronic idiopathic axonal polyneuropathy

The results of the last nerve conduction studies, performed prior to the questionnaire, were reviewed for presence of definite conduction block (segmental reduction in negative compound muscle action potential area of at least 50% in any nerve) and probable conduction block (segmental reduction in negative compound muscle action potential amplitude of at least 30% in an arm nerve) [27]. Conduction studies included the median nerve (recording from the thenar and flexor carpi radialis muscle), ulnar nerve, radial nerve, and musculocutaneous nerve up to Erb’s point, and the peroneal and tibial nerves up to the knee [27]. These nerves were studied bilaterally, except for five patients with CIDP and the patients with CIAP who were studied unilaterally. Conduction block in arm or leg nerves was found in all MMN patients, in 82% of CIDP patients, and in none of the PSMA or CIAP patients (Table 1). MMN patients had conduction block in arm nerves more often than CIDP patients.

Questionnaire

The questionnaire consisted of temperature-related and weakness-related items. Questions concerned the year preceding the questionnaire to reduce recall bias. First, we asked if symptoms of weakness and conditions of cooling or warming had occurred. Conditions of cooling included a stay in cold weather, the use of cold packs or taking a cold shower, bath or swim. Conditions of warming included a stay in hot weather, the use of hot packs or electric blankets, rinsing the hands in hot water while washing dishes or taking a warm or hot shower, bath or swim. If symptoms of weakness and conditions of cooling or warming had occurred, we asked if weakness increased during cooling (cold paresis) or warming (heat paresis). Exposure to cooling or warming and increase in weakness were entered as dichotomous variables. Prior to the study, the questionnaire was tested for inconsistencies and feasibility by a randomly chosen sample of 20 patients who visited our outpatient clinic for neuromuscular disorders with symptoms of weakness and who were not included in this study.

Statistical analysis

We calculated the frequency of symptoms of cold (or heat) paresis in arms with established weakness and in legs with established weakness. We determined if: (1) exposure to cooling and warming differed between patient groups, and (2) the percentage of patients with CIDP, PSMA, or CIAP reporting symptoms of cold or heat paresis differed from the percentage of patients with MMN reporting symptoms of cold or heat paresis (Chi-square tests).

Next, univariate and multivariate binary logistic regression analyses were performed. The determinant of interest was presence of MMN with CIDP, PSMA, and CIAP as reference groups. Outcome variables included: (1) symptoms of cold paresis in arms or legs, (2) symptoms of cold paresis in arms, (3) symptoms of cold paresis in legs, (4) symptoms of heat paresis in arms or legs, (5) symptoms of heat paresis in arms, and (6) symptoms of heat paresis in legs. Age and disease duration were assessed as continuous variables. The possible confounders sex, age (in years), and disease duration (in years) at the time of the questionnaire were added in the multivariate models.

Version 15.0.1 of the SPSS statistical software program (Chicago, IL, USA) was used for all analyses. p values <0.05 were considered to be significant.

Results

Exposure to cooling or warming did not differ significantly between MMN, CIDP, and PSMA, but CIAP patients were significantly less often exposed to cooling than MMN and PSMA patients (Tables 2, 3). Exposure to warming was more common than exposure to cooling and cold weather was the most common exposure to cooling. Despite this, patients reported cold paresis more often than heat paresis (Table 4).

Table 2.

Percentage of patients exposed to cooling

Patient group	Any	Bathing	Weather	Swimming	Cold pack
MMN	96	20	96	30	20
CIDP	90	23	88	29	8
PSMA	97	17	97	26	9
CIAP	72	8	72	8	4

MMN multifocal motor neuropathy; CIDP chronic inflammatory demyelinating polyneuropathy; PSMA progressive spinal muscular atrophy; CIAP chronic idiopathic axonal polyneuropathy

Table 3.

Percentage of patients exposed to warming

Patient group	Any	Bathing	Weather	Sauna	Hot pack	Electric blanket	Dish-washing
MMN	100	90	82	26	12	22	62
CIDP	98	92	90	19	2	13	65
PSMA	97	97	80	20	3	14	54
CIAP	96	76	60	0	0	20	52

MMN multifocal motor neuropathy; CIDP chronic inflammatory demyelinating polyneuropathy; PSMA progressive spinal muscular atrophy; CIAP chronic idiopathic axonal polyneuropathy

Table 4.

Percentage of patients reporting cold and heat paresis

Patient group	Cold paresis	p value	Heat paresis	p value
MMN	83	–	18	–
CIDP	44	<0.001	26	ns
PSMA	50	0.001	6	ns
CIAP	44	0.002	17	ns

p values refer to comparison with MMN

MMN multifocal motor neuropathy; CIDP chronic inflammatory demyelinating polyneuropathy; PSMA progressive spinal muscular atrophy; CIAP chronic idiopathic axonal polyneuropathy; ns not significant

Cold paresis in arms or legs was reported more frequently in MMN than in CIDP, PSMA, and CIAP (Table 4). Multivariate analysis showed that these differences were independent of sex, age, and disease duration, except for CIAP (Table 5). Patients with MMN had a fivefold higher risk of symptoms of cold paresis than patients with CIDP, and a sixfold higher risk than patients with PSMA. Multivariate analysis for symptoms of cold paresis in arms and legs separately, showed that these differences were still significant for the arms but not for the legs (Table 5).

Table 5.

Risk of cold paresis in MMN versus other disorders

Patient groups	Arm and leg	Odds ratio	p value	Arm	Odds ratio	p value
MMN–CIDP	Univariate	6.3 (2.4–16.6)	<0.001	Univariate	6.9 (2.4–20.0)	<0.001
	Multivariate	4.7 (1.7–13.4)	0.003	Multivariate	5.3 (1.7–16.7)	0.005
MMN–PSMA	Univariate	5.0 (1.8–13.8)	0.002	Univariate	3.4 (1.1–10.3)	0.03
	Multivariate	5.7 (1.8–18.1)	0.003	Multivariate	3.8 (1.04–14.3)	0.04
MMN–CIAP	Univariate	6.3 (1.9–20.8)	0.003
	Multivariate	4.0 (0.4–36.5)	ns

Odds ratios are given with 95% confidence intervals. Multivariate analysis was adjusted for age, sex, and disease duration. Cold paresis in arm muscles in the CIAP group was not analyzed because only two patients had upper limb weakness and were exposed to cold

MMN multifocal motor neuropathy; CIDP chronic inflammatory demyelinating polyneuropathy; PSMA progressive spinal muscular atrophy; CIAP chronic idiopathic axonal polyneuropathy; ns not significant

Heat paresis in arms or legs was not significantly more or less frequently reported in MMN than in CIDP, PSMA and CIAP (Table 4). Neither univariate nor multivariate analysis showed any significant differences between MMN and the other patient groups (data not shown).

Discussion

The present study demonstrated that cold paresis was experienced by a substantial proportion of patients with MMN, CIDP, PSMA, and CIAP. Cold paresis was more frequently reported than heat paresis. Cold paresis was more frequently reported in MMN than in CIDP, PSMA, or CIAP. Multivariate analysis indicated that MMN patients had a 4- to 6-fold greater risk of experiencing cold paresis than CIDP or PSMA patients. Because MMN predominantly affects arm nerves [27], we analyzed symptoms of cold paresis in arms and legs separately; this showed that these differences were still significant for the arms but not for the legs.

In MMN, electrophysiological, pathological, and immunological studies suggest that several mechanisms may be involved in the unique process that results in asymmetric loss of strength and muscular atrophy. Motor nerve conduction studies may show conduction block and slowing consistent with demyelination in the same segment; however, conduction velocity may also be normal in segments with motor conduction block [27, 28]. Some pathological studies of nerve branches containing motor and sensory axons showed demyelination but others only showed loss of axons [2, 5, 12, 24]. Needle electromyography studies showed extensive neurogenic abnormalities in non-atrophic as well as in atrophic muscles [26]. Excitability studies showed focal depolarization or hyperpolarization of motor axons of which the significance is not clear [14, 17]. In many MMN patients, antibodies against epitopes presented on the axolemma are found, and a recent study showed that these anti-GM1 antibodies are associated with loss of motor axons [3]. Thus, whereas demyelination clearly occurs in MMN, mechanisms leading to primary axonal degeneration may possibly occur as well. It is not clear if the conduction block is due to unfavorable effects of paranodal demyelination, blocking of impulse generation at the node, or both. Because MMN may lead to demyelination as well as loss of motor axons, we have chosen CIDP, PSMA, and CIAP as control groups in order to make a comparison to peripheral nervous system disorders that are also characterized by weakness: CIDP is characterized mainly by demyelination of motor and sensory axons, PSMA by loss of motor axons, and CIAP by length-dependent loss of motor and sensory axons.

Cold paresis was reported by two-thirds of patients with distal upper limb muscular atrophy (Hirayama disease), a disorder affecting peripheral motor neurons in the anterior horn of the cervical cord, which results in denervation of hand muscles [23]. Nerve conduction studies in 11 patients with Hirayama disease, and one patient with hypothenar atrophy due to ulnar neuropathy, showed that cold induced excessive conduction delay and waning of the compound muscle action potential during 20-Hz repetitive stimulation [15, 18]. These findings were attributed to an increased sensitivity of reinnervated muscle fibers to develop depolarizing conduction block in cold.

Cold paresis in MMN was suggested to be related to the existence of inflammatory nerve lesions where axons are depolarized but just able to conduct impulses at ambient temperature [11]. At these lesions, thermal reduction of Na/K-pump activity due to cooling may induce further depolarization to a point where impulse conduction fails. Some findings may support this hypothesis. First, animal models of inflammatory spinal root lesions indicated that inflammation may induce nitric oxide-mediated mitochondrial dysfunction, energy depletion of the ATP-ase dependent Na/K-pump, and axonal depolarization [13]. Secondly, excitability studies in MMN indirectly suggested that axons at the site of block may possibly be depolarized [14, 17]. Thirdly, cooling of normal human motor axons results in their depolarization, probably due to decreased Na/K-pump activity [7]. Some of the steps in this hypothesis were corroborated by experiments, but it must be emphasized, however, that its entire sequence has not been proven. Moreover, some experiments were carried out in central nervous system neurons so that the results possibly cannot be extrapolated to peripheral motor neurons.

Alternatively, cold paresis in MMN may be caused by development of conduction block in reinnervated muscle fibers due to the lower temperature [15, 18]. The possibility that this mechanism, which may be similar to that described in Hirayama disease, occurs in MMN is supported by several studies. Extensive needle electromyography studies in MMN patients showed signs of reinnervation, indicating collateral sprouting, in non-atrophic as well as in atrophic muscles [26]. Some pathological studies of motor nerves in MMN have shown prominent loss of axons and little demyelination; the loss of axons may lead to collateral sprouting and reinnervated muscle fibers [24].

In conclusion, symptoms of cold paresis occur in several peripheral nervous system disorders, but are considerably more common in MMN. Because the present study only assessed subjective symptoms of weakness, it is worthwhile to investigate if cold also induces an objective increase of weakness in MMN.

Abbreviations

CB

Conduction block

CIAP

Chronic idiopathic axonal polyneuropathy

CIDP

Chronic inflammatory demyelinating polyneuropathy

MMN

Multifocal motor neuropathy

PSMA

Progressive spinal muscular atrophy